title: Procoagulant activity in patients with sickle cell trait.
abstract: Patients with sickle cell trait (STr) are usually considered to be asymptomatic. However, complications, including hypercoagulability, increased risk of venous thromboembolism and the exertional exercise syndrome with rhabdomyolysis and sudden death, have been described. The exact cause of these adverse events is unclear. We have investigated two patients, a set of monozygotic twins with STr, to establish their procoagulant activity status as a potential indicator of thrombotic risk. In-vivo thrombin generation was assessed by the measurement of prothrombin fragment 1 + 2 (F1 + 2) and thrombin-antithrombin complexes (TAT). D-dimer was used as a marker of fibrinolytic activity. The potential to generate thrombin was determined using an ex-vivo thrombin generation test (TGT). The impact of red blood cell (RBC)-derived microparticle shedding and RBC rheology were examined. TAT (>60 μg/l) and F1 + 2 (948 pmol/l) were markedly elevated in patient 2 but within the normal reference range in patient 1 (TAT = 2.5 μg/l; F1 + 2 = 138 pmol/l). D-dimer levels (0.9 mg/l FEU) were similarly elevated in both patients. TGT peak thrombin and endogenous thrombin potential (ETP) were elevated to similar degrees in both patients. Flow cytometric analysis for RBC-derived microparticles showed that both patients had elevated levels on two occasions. RBC deformability, blood viscosity and RBC aggregation were normal and similar in both patients. The results demonstrated different coagulation activity in the patients with one patient in a prothrombotic state, suggesting that there may be two levels of hypercoagulability in STr. Measurement of such differences would allow for separation of high and low-risk patients from serious complications.
authors.affiliation: Department of Haematology, University College London, UK.
authors.forename: Andrew S
authors.initials: AS
authors.lastname: Lawrie
authors.forename: Arnold
authors.initials: A
authors.lastname: Pizzey
authors.forename: Sara
authors.initials: S
authors.lastname: Trompeter
authors.forename: Herbert
authors.initials: H
authors.lastname: Meiselman
authors.forename: Narla
authors.initials: N
authors.lastname: Mohandas
authors.forename: Jan P
authors.initials: JP
authors.lastname: Dumanski
authors.forename: Maxwell P
authors.initials: MP
authors.lastname: Westerman
mesh_terms: D000990:Antithrombin III; D001780:Blood Coagulation Tests; D004907:Erythrocyte Deformability; D004912:Erythrocytes / Q000166:cytology; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D006801:Humans; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood; D010447:Peptide Hydrolases / Q000097:blood; D011516:Prothrombin; D012307:Risk Factors; D012805:Sickle Cell Trait / Q000097:blood / Q000150:complications*; D019851:Thrombophilia / Q000097:blood / Q000209:etiology*; D013927:Thrombosis / Q000097:blood / Q000209:etiology*; D014427:Twins
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; D010446:Peptide Fragments; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; C045879:prothrombin fragment 1.2; D000990:Antithrombin III; D011516:Prothrombin; D010447:Peptide Hydrolases